The assisted reproductive technology market would grow at a CAGR of 8.12% over the predicted time frame. The market is expected to increase in value from US$ 28.44 Bn in 2022 to US$ 53.1 Bn in 2030.
Key Takeaways:
- Europe region has dominated the market in 2021 with a 37.8% of the revenue share.
- By product, the accessory & disposable segment accounted for 51% revenue share in 2021.
- By end-uses, the fertility clinics & other facilities segment has captured 79.9% of the overall revenue share in 2021.
- By type, the IVF segment has accounted for the highest revenue share of around 93.5% in 2021.
The on assisted reproductive technology Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2329
A recent report provides crucial insights along with application based and forecast information in the Global Assisted reproductive technology Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Assisted reproductive technology market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Assisted reproductive technology market are included as given below:
Assisted reproductive technology Market Key Players
- Vitrolife AB
- Thermo Fisher Scientific, Inc
- The Cooper Companies, Inc (Cooper Surgical Inc.)
- Progyny Inc.
- Oxford Gene Technology
- Millendo Therapeutics, Inc
- Merck KGaA (EMD Serono, Inc)
- Genera Biomedx
- Fujifilm Holdings Corporation (Irvine Scientific Sales Company)
- Cook Medical Inc
- Ferring B.V.
- Bloom IVF Centre
- European Sperm Bank
- Microm U.K. Ltd
- Cosmos Biomedical Ltd
- Cryolab Ltd
Market Segments
By Product
- Instrument
- Laser systems
- Micromanipulator
- Cabinet
- Ovum aspiration pump
- Imaging systems
- Incubator
- Cryosystem
- Sperm separation system
- Others
- Accessory & Disposable
- Reagents & media
- Embryo culture media
- Ovum processing media
- Semen processing media
- Cryopreservation media
By Technology
- In-Vitro Fertilization (IVF)
- Fresh Donor
- Frozen Donor
- Fresh Non-Donor
- Frozen Non-Donor
- Artificial Insemination
- Intrauterine Insemination
- Intracervical Insemination
- Intravaginal Insemination
- Intratubal Insemination
By Diagnosis
- Ovulation Testing
- Hysterosalpingography
By End-User
- Ambulatory surgical centers
- Hospitals
- Clinics
- Diagnostic centers
- Gynecology Centers
- Feminist Health Centers
- IVF Centers
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global assisted reproductive technology market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the assisted reproductive technology market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Assisted Reproductive Technology Market
5.1. COVID-19 Landscape: Assisted Reproductive Technology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Assisted Reproductive Technology Market, By Product
8.1. Assisted Reproductive Technology Market, by Product, 2022-2030
8.1.1. Instrument
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Accessory & Disposable
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Reagents & media
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Assisted Reproductive Technology Market, By Technology
9.1. Assisted Reproductive Technology Market, by Technology, 2022-2030
9.1.1. In-Vitro Fertilization (IVF)
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Artificial Insemination
9.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Assisted Reproductive Technology Market, By Diagnosis
10.1. Assisted Reproductive Technology Market, by Diagnosis, 2022-2030
10.1.1. Ovulation Testing
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Hysterosalpingography
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Assisted Reproductive Technology Market, By End-User
11.1. Assisted Reproductive Technology Market, by End-User, 2022-2030
11.1.1. Ambulatory surgical centers
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Hospitals
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Clinics
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Diagnostic centers
11.1.4.1. Market Revenue and Forecast (2017-2030)
11.1.5. Gynecology Centers
11.1.5.1. Market Revenue and Forecast (2017-2030)
11.1.6. Feminist Health Centers
11.1.6.1. Market Revenue and Forecast (2017-2030)
11.1.7. IVF Centers
11.1.7.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Assisted Reproductive Technology Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.2. Market Revenue and Forecast, by Technology (2017-2030)
12.1.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.1.4. Market Revenue and Forecast, by End-User (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Technology (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.1.5.4. Market Revenue and Forecast, by End-User (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Technology (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.1.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.2. Market Revenue and Forecast, by Technology (2017-2030)
12.2.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.2.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Technology (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.2.5.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Technology (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.2.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Technology (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.2.7.4. Market Revenue and Forecast, by End-User (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Technology (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.2.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.2. Market Revenue and Forecast, by Technology (2017-2030)
12.3.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.3.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Technology (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.3.5.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Technology (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.3.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Technology (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.3.7.4. Market Revenue and Forecast, by End-User (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Technology (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.3.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.2. Market Revenue and Forecast, by Technology (2017-2030)
12.4.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.4.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Technology (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.4.5.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Technology (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.4.6.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Technology (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.4.7.4. Market Revenue and Forecast, by End-User (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Technology (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.4.8.4. Market Revenue and Forecast, by End-User (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.2. Market Revenue and Forecast, by Technology (2017-2030)
12.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.5.4. Market Revenue and Forecast, by End-User (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Technology (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.5.5.4. Market Revenue and Forecast, by End-User (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Technology (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Diagnosis (2017-2030)
12.5.6.4. Market Revenue and Forecast, by End-User (2017-2030)
Chapter 13. Company Profiles
13.1. Vitrolife AB
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Thermo Fisher Scientific, Inc
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. The Cooper Companies, Inc (Cooper Surgical Inc.)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Progyny Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Oxford Gene Technology
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Millendo Therapeutics, Inc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck KGaA (EMD Serono, Inc)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Genera Biomedx
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Fujifilm Holdings Corporation (Irvine Scientific Sales Company)
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Cook Medical Inc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
0 Comments